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Vmax values on either the 19K4 apo(a) isoform or the 23K4Plasma and Lp(a)-associated PAF-acetylhydrolase activity in
isoform, was significantly higher in CAPD patients compareduremic patients undergoing different dialysis procedures.
with the other three groups.Background. Platelet-activating factor (PAF) is a potent in-
Conclusions. Plasma PAF-AH activity is increased in uremicflammatory mediator associated with several physiopathologi-
patients. This elevation is more profound in CAPD patients,cal conditions, including renal diseases. PAF is degraded to the
who also exhibit a more atherogenic lipid profile and moreinactive metabolite lyso-PAF by PAF-acetylhydrolase (PAF-
pronounced alterations in the specific activity and the kineticAH), which is considered as a potent anti-inflammatory and
constants of Lp(a)-associated PAF-AH.anti-atherogenic enzyme associated with lipoproteins. In this
study, we evaluated the plasma- and lipoprotein(a) [Lp(a)]-
associated PAF-AH activity in relationship to plasma lipid
parameters and Lp(a) isoform size in patients with mild/moder-
Platelet-activating factor (PAF; 1-O-alkyl-2-acetyl-sn-ate chronic renal failure (CRF), as well as in hemodialysis (HD)
glycero-3-phosphocholine) is a potent phospholipid me-and chronic ambulatory peritoneal dialysis (CAPD) patients.
Methods. We studied 74 patients undergoing maintenance diator in inflammatory and allergic reactions. PAF is
HD, 44 patients undergoing CAPD, 56 patients with mild/ considered to be significantly involved in several physio-
moderate CRF, and 98 healthy subjects whose lipid profile, as pathological conditions and may have pivotal roles inwell as plasma and high-density lipoprotein (HDL)-associated
several syndromes or diseases, including renal diseasesPAF-AH activity, was determined. Moreover, the effect of
[1–3]. It has been shown that PAF is produced in theLp(a) plasma levels on the distribution of PAF-AH among
plasma lipoproteins, as well as the specific activity and kinetic healthy kidney by endothelial, mesangial, and renal med-
properties of PAF-AH on two different Lp(a) isoforms, was ullary cells [4–6]. Studies in experimental animals and
measured in each studied group. in humans indicate that PAF may be an important media-Results. The plasma PAF-AH activity in all studied groups
tor of renal damage, suggesting that its production andwas significantly higher than in controls, and the increase was
action in the kidney may be dysregulated in disease statesmore profound in CAPD patients. The HDL-associated PAF-
AH activity, expressed per milliliter of plasma, was similar [3]. PAF has a short half-life time in plasma and is de-
among all studied groups; however, when it was expressed as graded to the inactive metabolite lyso-PAF by PAF-
either per milligrams of HDL cholesterol or per milligrams of
acetylhydrolase (PAF-AH; EC 3.1.1.47), which catalyzesplasma apolipoprotein (apo) AI, the PAF-AH activity was
the hydrolysis of the esterified acetate at the sn-2 positionsignificantly higher in all patient groups compared with con-
trols. All patient groups had significantly elevated plasma Lp(a) [7]. PAF-AH also hydrolyzes phospholipids containing
levels, which altered the distribution of PAF-AH among the oxidatively fragmented residues at the sn-2 position [8].
plasma lipoproteins compared with that observed in subjects Such phospholipids are formed during the oxidative
with very low plasma Lp(a) levels (,8 mg/dl). Additionally,
modification of low-density lipoprotein (LDL) and arein each studied group, the specific activity as well as the appar-
thought to play key roles in the inflammatory reactionsent Km and Vmax values of the 19K4 apo(a) isoform were signifi-
cantly higher (P , 0.01) compared with the values of the 23K4 and particularly in vascular inflammation and atheroscle-
isoform. However, the specific activity, as well as the Km and rosis [9]. Thus, PAF-AH could be a potent anti-inflam-
matory and antiatherogenic enzyme [10]. Human plasma
PAF-AH is associated with lipoproteins, especially withKey words: platelet-activating factor, PAF-acetylhydrolase, lipopro-
teins, renal failure, uremia, inflammation. LDL and high-density lipoprotein (HDL) [11, 12].
Changes in plasma PAF-AH have been reported in vari-Received for publication April 12, 1999
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nal function [14], whereas it has recently been reported shown in Table 1. The HD schedule was for four hours
three times per week using cuprophane or hemophanethat it was unaltered in patients with renal failure under-
hollow fiber dialyzers and acetate (N 5 6) or bicarbonategoing hemodialysis (HD) [15, 16].
(N 5 68) dialysate containing 2 g/liter glucose. CAPDLipoprotein(a) [Lp(a)] is an LDL-like particle distin-
patients performed four exchanges per day with two-guished from LDL by the presence of apolipoprotein(a)
liter solutions of 1.86 or 3.86% glucose, depending on[apo(a)], a high molecular mass glycoprotein that shows
the individual need for ultrafiltration. All patients hadremarkable size polymorphism, which is attached to apo
been free of peritonitis at least three months precedingB-100 through disulfide linkage [17, 18]. Apo(a) is highly
blood sampling. The method of replacement therapy washomologous to the plasma protease zymogen plasmino-
the initial treatment in most patients of both groups.gen, and thus, it has been suggested that Lp(a) may
Patients with a different method of replacement at thepromote thrombogenesis by inhibiting fibrinolysis [19,
onset of dialysis had to be on the present therapy for at20]. High plasma Lp(a) levels are considered to be an
least six months before their inclusion in the study. Theindependent risk factor for atherosclerosis in both Cau-
adequacy of the dialytic treatment was evaluated by thecasian and Oriental populations [21, 22]. In recent years,
Kt/V ratio, which ranged from 1.2 to 1.4 for HD patientsseveral reports have shown that serum Lp(a) concentra-
and from 1.9 to 2.0 (weekly) in CAPD patients. Patientstions are increased in patients with end-stage renal dis-
with mild/moderate CRF did not have significant pro-ease (ESRD) and that the Lp(a) serum concentration is
teinuria (urine protein ,1 g/24 hr). The renal diagnosisan independent factor contributing to the risk of athero-
for all patients was chronic pyelonephritis in 28 patients,sclerotic disease, which is the major cause of morbidity
chronic glomerulonephritis in 88 patients, hypertensiveand mortality in both HD and chronic ambulatory perito-
nephropathy in 6 patients, and polycystic kidney diseaseneal dialysis (CAPD) patients [23–27].
in 9 patients; the origin of CRF was unknown in theAs it has been shown previously [28, 29], Lp(a) is
remaining patients. Patients and controls with a knownenriched in PAF-AH, which is mainly associated with the
family history of primary hyperlipidemia, excessive alco-apo B rather than the apo(a) moiety of the lipoprotein
hol consumption, diabetes mellitus, obesity (body massparticle. We have also suggested that the apo(a) moiety
index .30 kg/m2), liver disease, systemic illnesses, orof Lp(a) affects the kinetic properties of the enzyme, as
other metabolic or endocrine disorders were excludedthe specific activity and apparent Km and Vmax values from the study. Patients received no other medicationare significantly decreased as the apo(a) isoform size
except polyvitamins, calcitriol, phosphate binders, andincreased [28]. Furthermore, using a gradient ultracen-
iron. In hypertensive patients, angiotensin-convertingtrifugation method, we have shown that in healthy sub-
enzyme inhibitors, calcium channel blockers, or both
jects, Lp(a) alters the enzyme distribution between LDL
were also given. In some CRF patients, frusemide 20 to
and HDL in a concentration-dependent fashion [28]. 60 mg/day per os was also administered. Thirty-one HD
To the best of our knowledge, there is a paucity of patients and 22 CAPD patients were on erythropoietin
data concerning PAF-AH activity in total plasma and in treatment.
Lp(a) of uremic patients undergoing dialysis. We under- Blood samples were taken in patients and controls
took this study in order to evaluate plasma PAF-AH after a 14-hour overnight fast for the determination of
activity in patients with mild/moderate chronic renal fail- serum lipid parameters, serum albumin, prealbumin, cre-
ure (CRF), as well as in HD and in CAPD patients and atinine, and PTH levels, as well as plasma PAF-AH
its association with lipid abnormalities, and to clarify, in activity. In HD patients, fasting blood was obtained be-
this clinical context, Lp(a)-associated PAF-AH activity, fore dialysis, whereas in 30 HD patients, blood was also
as well as the Lp(a) isoform-dependent effect on the taken immediately after dialysis for the determination
enzyme-specific activity and kinetic constants. of PAF-AH activity. In CAPD patients, fasting venous
blood was drawn without interruption of CAPD. In pa-
tients with CRF, proteinuria was determined on 24-hourMETHODS
urine samples, and creatinine clearance was also calcu-
Study population lated. In dialysis patients, the residual renal function
Seventy-four patients undergoing maintenance HD, estimated by the average of the residual creatinine and
44 patients undergoing CAPD, 56 patients with mild/ urea clearances was almost negligible (,5.0 ml/min).
moderate CRF (serum creatinine 1.8 to 8 mg/dl, and
Analytical methodscreatinine clearance 10 to 60 ml/min), and 98 subjects
selected from individuals receiving medical check-up at Serum cholesterol and triglycerides were determined
our hospital who were free from any illness by history, by enzymatic colorimetric assay using an RA-1000 ana-
physical examination, and routine laboratory data (con- lyzer (Technicon Instruments, Tarrytown, NY, USA),
whereas HDL cholesterol was determined enzymaticallytrol group) were studied. Population characteristics are
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Table 1. Clinical and laboratory characteristics of the study population
Controls HD patients CAPD patients CRF patients P
Number 98 74 44 56
Age years 57.0 (28–79)a 59.0 (30–81) 58.5 (48–79) 56.5 (39–80) NS
Sex females/males 43/55 31/43 17/27 23/33 NS
BMI kg/m2 23.562.1 23.1 61.7 23.6 62.2 22.861.7 NS
Duration of dialysis months — 60 (9–115)a 55 (8–118) — NS
Serum albumin g/dl 4.560.3 3.6 60.3 3.7 60.6 4.160.4 0.05b
Serum prealbumin mg/dl 29.466.2 37.8 69.4 32.5 67.5 36.868.7 0.05b
Serum PTH pg/ml 34616 3206270 296 6302 1346141 0.001c
SBP mm Hg 13069 136 612 135 611 138610 0.05b
DBP mm Hg 8066 86 65 85 66 8767 0.05b
Values represent either the mean 6 sd, or the a median (range). Abbreviations are: HD, hemodialysis; CAPD, chronic ambulatory peritoneal dialysis; CRF,
undialyzed patients with mild/moderate chronic renal failure; PTH, parathyroid hormone; SBP, systolic blood pressure; DBP, diastolic blood pressure; NS, not
significant differences among the studied groups.
b By one-way analysis of variance
c By Kruskal–Wallis test
in the supernatant after precipitation of other lipopro- Lipoprotein(a) isolation
teins with dextran sulfate-magnesium. LDL cholesterol Three subjects from each patient group and controls
was calculated using the Friedewald formula [30] if fast- presenting with a single apo(a) isoform band of either
ing triglyceride levels were less than 400 mg/dl. Serum 19 K4 or 23 K4 and with plasma Lp(a) levels higher than
apo AI and apo B were measured by immunonephe- 20 mg/dl were selected in order to isolate Lp(a) and study
lometry with the aid of a Beckman array analyzer (Beck- the kinetic properties of PAF-AH. Lp(a) was isolated
man Instruments, Palo Alto, CA, USA). Lp(a) was mea- by density gradient ultracentrifugation followed by gel
sured using a monoclonal anti-Lp(a) antibody technique filtration chromatography on Sepharose 6B column, as
described previously [28]. To avoid any oxidation, Lp(a)by the enzyme immunoassay Macra Lp(a) (Terumo
was prepared in the presence of 0.3 mm ethylenediamine-Medical Corporation Diagnostic Division, Elkton, MD,
tetraacetic acid (EDTA). Furthermore, Lp(a) prepara-USA). Serum and urine creatinine were measured by
tions were stored in the presence of EDTA at 48C underthe Jaffe´ method and serum albumin by the bromocresol
nitrogen and were used within two weeks. The absencegreen method. Serum prealbumin was measured by im-
of oxidation in our Lp(a) preparations was confirmedmunonephelometry, and serum parathyroid hormone
by agarose gel electrophoresis (Hydragel Lipo1Lp(a)(PTH) levels were measured by radioimmunometric
kit; Sebia), as well as by the thiobarbituric acid reactiveassay [24, 25].
substances (TBARS) assay [33]. The Lp(a) preparations
were essentially free of any other lipoprotein or albuminApolipoprotein(a) phenotyping
as evaluated by both nondenaturing 2 to 16% gradientApolipoprotein(a) isoform size was determined by
polyacrylamide gel electrophoresis (PAGE) [34] and byagarose gel electrophoresis in 1.5% sodium dodecyl sul-
gradient 5 to 19% SDS-PAGE, followed by immunoblot-fate (SDS)-agarose gels followed by immunoblotting,
ting using sheep polyclonal anti-apo(a) and anti-apo B-100according to the method of Kamboh, Ferrell, and Kottke
antibodies and revealed by chemiluminescence. The lipid
[31], as modified by Doucet et al [32]. Isoform size was
content of Lp(a), that is, cholesterol, triglycerides, and
expressed as number of kringle 4 (K4) repeats by using phospholipids, was analyzed by enzymatic methods using
a standard with five different apo(a) isoforms (35, 27, 23, BioMerieux kits (Marcy l’Etoile, France) and the protein
19, and 14 K4) obtained from Immuno AG (Innsbruck, content by the bicinchoninic acid method. Lipoprotein
Austria). mass was calculated as the sum of all lipid and protein
components. Lp(a) was stored under nitrogen and usedFractionation of plasma lipoproteins
within two weeks after preparation.
Plasma lipoproteins were fractionated by density gra-
Platelet-activating factor-acetylhydrolase assaydient ultracentrifugation in a Beckman L7-65 ultracentri-
fuge at 40,000 r.p.m., 158C for 24 hours, using a type SW Platelet-activating factor-AH activity was measured
41 rotor as described previously [28]. After ultracentrifu- by the trichloroacetic acid (TCA) precipitation proce-
gation 28 fractions of 400 ml were collected by successive dure [12]. A [3H]-PAF solution with a concentration of
aspiration from the meniscus downward. All fractions 1 mm (specific activity 2000 cpm/nmol) containing PAF
were analyzed for their cholesterol and Lp(a) content (hexadecyl; Bachem, Zurich, Switzerland), and 1-O-hex-
adecyl-2-[3H-acetyl]-sn-glycero-3-phosphocholine (10 Ci/as well as for their PAF-AH activity.
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mmol; DuPont-New England Nuclear, Boston, MA, patients exhibited significantly higher serum total choles-
terol, LDL cholesterol, and apo B levels compared withUSA), 1 mmol/liter, prepared as previously described
[12], was used as a substrate for PAF-AH. The enzyme the other patient groups or controls. Moreover, the ath-
erogenic risk ratio of total cholesterol/HDL cholesterolactivity in plasma or HDL was measured as already men-
tioned [35]. PAF-AH activity was also determined in 25 was significantly higher in this patient group compared
with HD or CRF patients. All patient groups had in-ml of each gradient fraction and on Lp(a) using 10 mg
of Lp(a) protein [28]. The reaction was performed for creased serum Lp(a) concentrations when compared
with controls (Table 2). Although CAPD patients exhib-10 minutes at 378C by adding 10 ml of [3H]-PAF (100
mmol/liter final concentration). PAF-AH activity was ex- ited higher serum Lp(a) levels than HD and CRF pa-
tients, the differences were not statistically significant.pressed as nmol PAF degraded per minute per ml of
plasma or per mg HDL cholesterol or per mg apo AI. In none of the patients’ groups were serum Lp(a) concen-
trations correlated with the other lipid parameters orLp(a)-associated PAF-AH activity was expressed per
mg of Lp(a) protein or mg of Lp(a) mass. The kinetic age or with serum creatinine, albumin, prealbumin, or
PTH levels. Additionally, no correlation between serumproperties of Lp(a)-associated PAF-AH were evaluated
in each isoform using 2.5 to 100 ml [3H]-PAF final concen- Lp(a) concentrations and dialysis duration was present
in either dialysis group.tration as described [28]. The apparent Km and Vmax val-
ues of the enzyme were calculated using the Lineweaver-
Plasma and HDL-associated PAF-AH activityBu¨rk representation of the data.
As shown in Figure 1, the plasma PAF-AH activity
Statistical analysis in all patient groups was higher than controls (P , 0.005
for CRF and HD before dialysis and P , 0.001 for CAPDValues are expressed as mean 6 sd, except for age
and Lp(a), which are expressed in terms of median and patients). Additionally, the enzyme activity in CAPD
patients was significantly higher compared with eitherrange. A comparison of continuous variables was per-
formed by unpaired two-tailed t-test, as well as by one- HD or CRF patients (P , 0.001 for both comparisons),
whereas no difference was observed between HD andway analysis of variance with multiple Scheffe-type com-
parisons. Because of the highly skewed distribution of CRF patients. The enzyme activity also studied in 30
HD patients immediately after dialysis revealed no dif-PTH and Lp(a), the nonparametric Mann–Whitney U-test
and the Kruskal–Wallis test were applied to discriminate ference compared with that observed before dialysis
(68.8 6 13.6 vs. 64.4 6 15.6 nmol/ml/min, respectively,for differences of these parameters between groups. The
distribution of plasma PAF-AH activity was tested for P 5 NS). No significant differences in the plasma PAF-
AH activity were observed in HD patients using cupro-normality using the Kolmogorov Smirnov test. Because
the PAF-AH activity values did not significantly differ from phane compared with those using hemophane hollow
fiber dialyzers (data not shown). The PAF-AH activitynormal distribution in all studied groups, one-way analy-
sis of variance (with Fisher’s least significant difference in controls, HD, and CRF patients was correlated with
total cholesterol, LDL cholesterol, and apo B levels (Ta-method for multiple comparisons) was used to compare
PAF-AH activity among groups. The same procedure was ble 3). Additionally, in all patient groups, the enzyme
activity was correlated with the triglyceride levels (Tableused to assess the differences in specific activity and
kinetic constants of PAF-AH associated with two different 3). Interestingly, in CAPD patients, no correlation was
observed between the plasma PAF-AH activity and totalapo(a) isoforms. Correlations between PAF-AH activity
and covariates were estimated using Pearson’s correla- cholesterol, LDL cholesterol, or apo B levels, whereas
an inverse correlation with HDL cholesterol and apo AItion coefficients. Spearman’s rank correlation coefficients
were used to evaluate the degree of association between levels was noticed (Table 3). PAF-AH activity was not
significantly correlated with Lp(a) levels in all studiedLp(a) and other values. Pearson’s x2 test was used to
assess the difference in prevalence between the studied groups, although the correlation coefficient values in all
patient groups were higher compared with controls (Ta-groups. Significance levels were set at 0.05 in all cases.
ble 3). No correlation was found between the enzyme
activity and the mean blood pressure values in all studied
RESULTS
groups (data not shown). Finally, the plasma enzyme
Patients’ lipid profile activity in CRF patients was not correlated with plasma
creatinine levels or with creatinine clearance values (Ta-As shown in Table 2, all patient groups had signifi-
cantly increased serum triglyceride and decreased HDL ble 3).
The HDL-associated PAF-AH activity, expressed percholesterol and apo AI levels compared with controls.
The atherogenic risk ratio of total cholesterol/HDL cho- milliliter of plasma, was similar among all studied groups
(6.2 6 3.2 nmol/ml plasma/min for controls, 6.6 6 1.6 forlesterol was also significantly higher in all patient groups
in comparison with normal subjects. Interestingly, CAPD HD patients, 6.7 6 1.1 for CAPD, and 6.6 6 1.4 for CRF
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Table 2. Serum lipid parameters in patients and controls
Control population HD patients CAPD patients CRF patients
Parameters (N 5 98) (N 5 74) (N 5 44) (N 5 56) Significance
Total-C mg/dl 201631 198640 238642b,c 206636 ,0.01
HDL-C mg/dl 52612 42612a 3767b 43614d ,0.01
LDL-C mg/dl 124629 117634 154638b,c 127631 ,0.01
Total-C/HDL-C 3.961.0 4.761.5a 6.461.7b,c 4.861.5d ,0.001
Triglycerides mg/dl 121651 208672a 212664b 174673d ,0.01
Apo AI mg/dl 154625 131624a 125614b 134624d ,0.01
Apo B mg/dl 125631 132628 161647b,c 137632 ,0.01
Lp(a) mg/dl 6.0 (0.8–68) 18.4 (0.8–147)e 21.3 (0.8–105)f 17.5 (0.8–102)e ,0.001 (Kruskal-Wallis)
Abbreviations are: Total-C, total cholesterol; HDL-C, HDL cholesterol; LDL-C, LDL cholesterol; Apo AI, apolipoprotein AI; Apo B, apolipoprotein B; Lp(a),
lipoprotein (a); HD, hemodialysis; CAPD, chronic ambulatory peritoneal dialysis; CRF, chronic renal failure. Values represent mean 6 sd, except for Lp(a), which
is expressed as median value (range). The difference in the four groups was analyzed by one-way ANOVA, except for Lp(a) differences that were analyzed by
Kruskal-Wallis test.
Significant difference: a Control vs. HD, b control vs. CAPD, c CAPD vs. either HD or CRF, d control vs. CRF, as assessed by multiple comparison (Scheffe type)
e P , 0.01 compared to control population (Mann-Whitney U test)
f P , 0.001 compared to control population (Mann-Whitney U test)
group with Lp(a) levels ranging from 31 to 51 mg/dl
was fractionated into 28 fractions by density gradient
ultracentrifugation. Lp(a) was not detectable in any gra-
dient fraction or it was migrated as a narrow band in
fractions 12 to 15 (d 5 1.064 to 1.095) in the plasma of
subjects with Lp(a) levels ,8 mg/dl. By contrast, in
plasma with Lp(a) levels 31 to 51 mg/dl, it was migrated
in fractions 9 to 17 (d 5 1.050 to 1.100 g/ml) indepen-
dently of the apo(a) isoform size, as we have previously
reported [28]. A representative curve of the lipoprotein
profile obtained is shown in Figure 3A. No difference in
the PAF-AH activity (expressed as a percentage of the
total activity recovered in all gradient fractions) was ob-
served among all studied groups for the same range of
Lp(a) concentrations (Fig. 3B). By contrast, the enzyme
activity distributed in fractions 9 to 17 was significantlyFig. 1. Plasma platelet-activating factor-acetylhydrolase (PAF-AH)
activity in the study population. PAF-AH activity was determined by higher in subjects with Lp(a) plasma levels 31 to 51 mg/dl,
the TCA precipitation method, by using 50 ml of plasma (diluted 1:50 as compared with those with Lp(a) levels ,8 mg/dl (P ,
vol/vol with HEPES buffer) as the source of the enzyme. Data are
0.04 for all groups; Fig. 3B). In plasma with Lp(a) levelsexpressed as means 6 sd. *P , 0.05 compared with controls; **P ,
0.001 compared with controls; †P , 0.001 compared with hemodialysis ,8 mg/dl, the fractions 1 to 8 [very low density lipopro-
(HD) as well as chronic renal failure (CRF). tein (VLDL) plus the major part of LDL] contained
19.5 6 3.2% of total enzyme activity in all studied groups
and the fractions 18 to 28 (the major part of HDL plus
proteins) contained 33.4 6 5.2%. Finally, in plasma withpatients). It is important to note that the HDL-associated
Lp(a) levels 31 to 51 mg/dl, the fractions 1 to 8 containedPAF-AH activity when expressed as either per milligram
20.1 6 5.3% of total enzyme activity in all studied groups,of HDL cholesterol or per milligram of plasma apo AI
and the fractions 18 to 28 contained 24.6 6 4.8%, whichwas significantly higher in all patient groups compared
was significantly lower (P , 0.04) compared with thewith controls (Fig. 2). Also, similar results for the enzyme
same fractions from plasma with Lp(a) levels ,8 mg/dl.activity in plasma or in HDL were obtained when the
patients receiving calcitriol, angiotensin-converting en-
PAF-AH activity on different Lp(a) isoformszyme inhibitors, calcium channel blockers, or frusemide
Lipoprotein(a) isoforms with 19 K4 repeats or 23 K4were excluded from the statistical analysis.
repeats were isolated from three subjects of each group
Effect of Lp(a) on the distribution of PAF-AH who had plasma Lp(a) levels higher than 20 mg/dl,
activity among plasma lipoproteins after whereas the Lp(a) mass as well as the PAF-AH specific
gradient ultracentrifugation activity and kinetic constants were determined on each
isoform. No oxidation was observed in each Lp(a) prepa-Plasma from six subjects of each studied group with
Lp(a) levels ,8 mg/dl and from six subjects of each ration, as its electrophoretic mobility in agarose gels was
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Table 3. Correlations between plasma PAF-AH activity and lipid parameters
Correlation coefficient
Lipid parameter Controls HD patients CAPD patients CRF patients
Total cholesterol 0.46c 0.75c 0.31 0.78c
Triglycerides 0.12 0.48b 0.56b 0.47b
LDL cholesterol 0.51c 0.68c 0.23 0.75c
HDL cholesterol 20.17 20.16 20.53b 20.16
Apo AI 20.13 20.18 20.46a 20.09
Apo B 0.61c 0.81c 0.29 0.72c
Lipoprotein(a) 20.007 0.13 0.19 0.17
Serum creatinine 20.07
Creatinine clearance 20.05
Abbreviations are: PAF-AH, platelet-activating factor acetylhydrolase; HD, hemodialysis; CAPD, chronic ambulatory peritoneal dialysis; CRF, undialyzed patients
with mild/moderate chronic renal failure.
a P , 0.05
b P , 0.001
c P , 0.0001
not different than that of the Lp(a) band obtained after CRF who received HD [16]. Unlike these results, our
study showed that HD patients exhibit significantlyplasma electrophoresis of the same subject. Additionally,
higher enzyme activity compared with controls. Further-the TBARS values were 0.9 6 0.3 nmol of malondialde-
more, PAF-AH activity in patients with mild/moderatehyde equivalents per mg of Lp(a) protein. The Lp(a)
CRF was not different from that of HD patients, whereasmass was not different between the two isoforms in all
no correlation between serum creatinine levels or creati-studied groups (0.6 6 0.2 mg/ml plasma). As shown in
nine clearance values and plasma PAF-AH activity wasTable 4, the PAF-AH specific activity, as well as the
observed in this patient group. Thus, these results pro-apparent Km and Vmax values of the 19 K4 apo(a) isoform,
vide evidence that the degree of the renal dysfunctionin each studied group, was significantly higher compared
does not influence the plasma PAF-AH activity and fur-with the values of the 23 K4 isoform of the same group
ther confirm the observation of other studies indicating(P , 0.01 for all comparisons). It is also important to
that the kidney is not a major source of the plasmanote that the specific activity as well as the Km and Vmax
enzyme pool [14, 15]. Our study also shows that thevalues on either the 19 K4 apo(a) isoform or the 23
plasma PAF-AH activity is significantly higher in CAPDK4 isoform in CAPD patients were significantly higher
patients compared with HD or CRF patients, suggestingcompared with the values of the same apo(a) isoform in
an association between plasma PAF-AH activity andthe other patient groups as well as in controls (Table 4).
dialysis procedure.
It is well documented that CRF is a clinical state of
DISCUSSION impaired immunoreactivity with high susceptibility to
In this study, we showed that the plasma PAF-AH infections [36]. Several studies have demonstrated the
activity is increased in patients with renal failure with presence of inflammatory mediators in an ongoing acute-
or without renal replacement therapy. This elevation in phase reaction in CRF patients not requiring dialysis, as
the enzyme activity was more pronounced in patients well as in patients with ESRD undergoing HD or CAPD
undergoing CAPD. All patient groups had significantly [37, 38]. In this context, an association between severe
higher plasma levels of Lp(a), which alter the distribution renal disease (that is, CRF, primary glomerulonephritis)
of PAF-AH among the plasma lipoproteins. The specific and increased PAF production leading to elevated plasma
activity and kinetic constants of PAF-AH associated with PAF levels has been reported, whereas PAF may have
Lp(a) of two different isoforms with 19 K4 repeats or a prominent role in renal glomerular pathology [14, 15].
23 K4 repeats were significantly higher in CAPD patients Thus, the increase in plasma PAF-AH activity found in
compared with the other patient groups or with controls, this study may represent a protective response to the
whereas no difference was observed between controls inflammatory actions of PAF. Alternatively, it has been
and HD or CRF patients. previously shown that the plasma PAF-AH activity is
Changes in plasma PAF-AH activity have been re- increased in both clinical and experimental hypertension
ported in various diseases [13], although in most of these [39, 40]. Because PAF is a strong hypotensive agent [41],
studies, the mechanisms underlying the reported alter- the increase in plasma PAF-AH activity may well be part
ations in the enzyme activity are not clear yet. Especially of a regulatory counter-response mechanism in arterial
in renal failure, only recently was it reported that the blood pressure homeostasis. However, according to our
results, the plasma PAF-AH activity was not related toplasma PAF-AH activity is unaltered in patients with
Milionis et al: PAF-AH in CRF2282
Fig. 2. High density lipoprotein (HDL)-associated PAF-AH activity
expressed (A) per mg plasma HDL cholesterol, and (B) per mg plasma
apolipoprotein AI (apo AI) in the study population. PAF-AH activity
was determined by the TCA precipitation method by using 50 ml of
Fig. 3. (A) Representative curve of the lipoprotein profile obtainedthe HDL-containing supernatant after treatment of plasma with magne-
after density gradient ultracentrifugation of plasma. (B) Distributionsium-dextran sulfate (diluted 1:5 vol/vol with HEPES buffer) as the
of PAF-AH activity in gradient fractions 9 to 17 (d 5 1.050 to 1.100source of the enzyme. Data are expressed as means 6 sd. *P , 0.05
g/ml) containing the Lp(a). Ultracentrifugation was performed using acompared with controls.
type SW 41 rotor at 40,000 r.p.m., 158C for 24 hours, and PAF-AH
activity was determined by the TCA precipitation method, by using
25 ml of gradient fractions as the source of the enzyme. Data are
expressed as means 6 sd.
blood pressure values in all studied groups. Additionally,
the more profound increase in the plasma PAF-AH activ-
ity in CAPD patients can not be explained by this assump-
[37]. Thus, it is unlikely that the increased PAF-AHtion, as there were no significant differences in the mean
activity in the plasma of these patients is due to enhancedblood pressure values among the patient groups.
secretion from macrophages. It has been reported thatIndeed, in this study, we do not provide experimental
PAF stimulates the synthesis and secretion of PAF-AHdata for the mechanisms responsible for the increased
from the liver [45]. Consequently, because of the in-PAF-AH activity in the plasma of our patients. However,
creased PAF production in renal failure, it is more likelyit is known that the major sources of the plasma enzyme
that the liver may be the main source of the increasedare monocyte-derived macrophages and liver cells [42,
PAF-AH in plasma of these patients. Additionally, in43]. The secretion of PAF-AH from macrophages is sup-
patients with renal failure and especially in CAPD pa-pressed in the presence of various cytokines, such as
tients, a stimulation of hepatic synthesis of proteins astumor necrosis factor-a and interleukin-1b [44], which
are increased in the plasma of patients with renal failure well as of lipoproteins is observed [46]. This pronounced
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Table 4. Specific activity and kinetic constants of PAF-AH associated with two different Lp(a)
isoforms in patients with renal failure and controls
Vmax Specific activity
Km, lm nmol/mg protein/min nmol/mg Lp(a) mass/min
Subjects 19K4 23K4 19K4 23K4 19K4 23K4
Controls 45.962.1 26.8 60.6 29.360.9 17.8 60.8 10.8 60.4 6.5 60.1
HD patients 45.163.9 26.5 61.7 29.662.5 18.3 61.0 10.9 60.9 6.5 60.4
CRF patients 46.862.2 25.5 60.5 30.261.6 17.4 61.1 11.2 60.8 6.4 60.1
CAPD patients 67.263.3b 3761.5b 34.261a 19.460.6a 12.760.4a 7.160.2a
Abbreviations are: HD, hemodialysis; CAPD, chronic ambulatory peritoneal dialysis; CRF, undialyzed patients with mild/moderate chronic renal failure. Values
represent the mean 6 sd from three different Lp(a) preparations. The kinetic constants in each preparation were measured in duplicate.
a P , 0.05
b P , 0.001 compared to the values of the other studied groups for the same isoform
hepatic secretion of proteins may also explain the sig- patient groups compared with controls. Like previous
studies, a strong correlation between plasma PAF-AHnificantly higher enzyme activity in CAPD patients com-
pared with CRF or with HD patients. Because it has been activity and LDL cholesterol levels was found in all
groups except for CAPD patients. It has been suggestedhypothesized that the secretion of the enzyme occurs
independently of the secretion of lipoprotein particles that the correlation observed between these two parame-
ters reflects a process that is probably the rate of LDLand then it associates with them [47], a direct increased
synthesis of PAF-AH might be the underlying mecha- clearance, which influences both of these variables [51].
This could also explain the positive correlation betweennism of the increased enzyme activity in this population.
The HDL-associated enzyme activity expressed per PAF-AH activity and apo B levels revealed in our study.
The absence of such a correlation in CAPD patients ismg of HDL cholesterol or mg of apo AI was significantly
higher in the patient groups compared with controls, intriguing and may be related to a more pronounced
derangement of lipid metabolism characterizing this dial-suggesting an enrichment of HDL with PAF-AH activity.
However, when the enzyme activity was expressed per ml ysis procedure. In fact, the elevated hepatic lipoprotein
secretion consequent upon protein losses in the dialysisof plasma, it was similar among all groups, because of
the lower HDL cholesterol levels observed in the patient fluid and increased carbohydrate absorption via the peri-
toneum is of paramount importance for the developmentgroups compared with controls. It has been suggested that
the HDL-associated paraoxonase and PAF-AH activities of dyslipidemia in these patients [46]. Thus, an increased
LDL synthesis rather than a retarded LDL clearance iswork in concert to detoxify the lipid peroxides formed
on LDL during oxidation, thus providing HDL with an the main mechanism responsible for the increased LDL
levels in CAPD patients [46], leading to the absence ofanti-atherogenic potency [48]. The increased HDL-asso-
ciated PAF-AH activity found in our patients could correlation between PAF-AH activity (dependent on the
rate of LDL removal) and LDL cholesterol levels.counteract the reduced paraoxonase activity observed
by some investigators in such patients, which could result Significantly elevated plasma Lp(a) concentrations, a
typical feature of uremic dyslipidemia [23–27], were ob-in a decreased HDL antioxidant capacity [16, 49].
All patient groups exhibited a moderate hypertriglyc- served in all patient groups. We have already stated that
the distribution of PAF-AH among the LDL and HDLeridemia, which is a characteristic feature of uremic dys-
lipidemia [50]. Our results show that the PAF-AH activ- subfractions in plasma studied by density gradient ultra-
centrifugation is influenced by the plasma Lp(a) levelsity is positively correlated with plasma triglyceride levels
in all patient groups but not in controls. This association in an Lp(a) concentration-dependent fashion [28]. Our
results confirm these observations showing that the pres-between PAF-AH and serum triglycerides has already
been observed, although the biochemical mechanism(s) ence of Lp(a) in plasma alters the distribution of PAF-AH
among the plasma lipoproteins, as the PAF-AH activityfor this correlation has not been yet elucidated [51, 52].
Although PAF-AH activity has been found on VLDL in the density region of Lp(a) (fractions 9 to 17) is in-
creased accompanied by a decrease in fractions 18 to 28[12, 53], an elevation in plasma VLDL concentration
does not increase the plasma PAF-AH activity, an indica- in subjects from all studied groups having plasma Lp(a)
levels 31 to 51 mg/dl compared with those with Lp(a)tion suggesting that any correlation between plasma
PAF-AH activity and triglyceride levels is unlikely to levels ,8 mg/dl. However, the distribution of PAF-AH
activity in these gradient fractions was not differentreflect a direct causal association between these two pa-
rameters [51]. Accordingly, our density gradient ultra- among the studied groups with the same range of plasma
Lp(a) levels despite the significant differences in thecentrifugation experiments showed no increase in the
enzyme activity associated with fractions 1 to 8 in all plasma enzyme activity among these groups. Accord-
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